Highest-materiality recent filing
All seven director nominees elected at the Oct 14, 2026 annual meeting; Brian Alexander (8,241,264 for) and Scott Tobin (8,230,372) drew the least opposition.
Champions Oncology Q1 revenue up 8.8% to $15.2M; adjusted EBITDA $671K vs $59K
Revenue $15.2M, +8.8% YoY; oncology services margin improved to 51% from 43%.
Record annual revenue $59.4M, up 4% YoY; Q4 revenue $13.8M, up 12% YoY.
Champions Oncology appoints Dr. Brian Alexander to board, replacing Dr. Philip Breitfeld
Board accepted resignation of Dr. Philip Breitfeld and appointed Dr. Brian Alexander effective March 24, 2026.
Record study service revenue $16.6M, up 32% YoY; total revenue $16.6M vs $17.0M prior year.
Champions Oncology Q2 revenue up 11% to $15M; net income $237K, adj EBITDA $843K; positive outlook
Q2 total revenue $15.0M (+11% YoY); oncology services profit $7.8M, margin 52% vs 45%.
All seven director nominees elected; top vote-getter Scott R. Tobin with 9,722,734 votes for.
Revenue $14.0M, down from $14.1M YoY; operating loss of $527K vs income of $1.3M.
Champions Oncology reports record annual revenue $57M (+14%), net income $4.6M for FY2025
Record annual revenue $57M, up 14% YoY; net income $4.6M vs loss of $7.4M prior year.
Champions Oncology appoints Robert Brainin as CEO effective Aug 25, 2025
Robert Brainin named CEO, effective August 25, 2025; he was a Board member since Feb 2021.
Revenue up 42% YoY to $17.0M; net income of $4.5M vs loss of $2.6M in prior year quarter.
Champions Oncology Q2 FY2025: Revenue $13.5M, Net Income $730K, Adj. EBITDA $1.1M
Q2 revenue rose 17% YoY to $13.5M; gross margin improved to 45% from 43%
Seven director nominees elected with majority votes; Ronnie Morris, M.D. received 8,483,091 for and 685,123 withheld.
Champions Oncology President Brady Davis passes away unexpectedly
President Brady Davis passed away unexpectedly in the week ending October 3, 2024.
Champions Oncology Q1 revenue $14.1M, net income $1.3M, adjusted EBITDA $2.0M
Revenue rose 12% YoY to $14.1M; net income of $1.3M vs. loss of $2.6M a year ago.
Champions Oncology reports FY2024 revenue down 7% to $50.2M; Q4 adjusted EBITDA turns positive $884K
Q4 revenue $14.0M (+7% YoY); Q4 adjusted EBITDA income $884K vs loss $922K prior year.
Champions Oncology Q3 revenue down 6% to $12.0M; operating loss widens to $2.6M
Q3 FY2024 revenue $12.0M, down from $12.8M YoY; gross margin fell to 34.7% from 39.7%.
Champions Oncology Q2 revenue $11.6M (-19% YoY); revises FY2024 guidance to flat
Operating loss of $2.0M vs $7K income a year ago; adjusted EBITDA loss of $1.4M.
All seven director nominees elected; Scott Tobin and Philip Breitfeld each received over 9.6M votes for.
Champions Oncology appoints Brady Davis as President, effective Oct 9, 2023
Brady Davis appointed President; annual base salary of $425,000 plus 50% target bonus.
Champions Oncology Q1 revenue $12.6M, down 9%; operating loss widens to $2.6M
Revenue $12.6M vs $13.7M YoY (-8.6%); gross margin 38.8% vs 48.7%.
Q4 operating loss of $2.5M vs $311K loss a year ago; includes $807K asset impairment on Lumin platform.
Champions Oncology announces $5M share repurchase program through April 2024
Board authorized up to $5M of common stock repurchases through April 30, 2024.
Champions Oncology Q3 revenue $12.8M (-3.2% YoY), operating loss $2.5M, adj EBITDA -$1.6M
Revenue declined 3.2% to $12.8M from $13.2M a year ago, driven by macro-related customer cancellations.
Champions Oncology reports record Q2 revenue of $14.3M, cuts FY growth outlook to 10-15%
Record quarterly revenue of $14.3M, up 21% YoY from $11.8M.
Champions Oncology stockholders elect all seven director nominees at 2022 Annual Meeting
Seven directors elected: Ronnie Morris, Joel Ackerman, David Sidransky, Daniel Mendelson, Robert Brainin, Scott Tobin, Philip Breitfeld.
Champions Oncology Q1 record revenue $13.7M (+22% YoY); adjusted EBITDA $450K
Record quarterly revenue $13.7M, up 22% from $11.3M in prior year quarter.
Champions Oncology reports record FY2022 revenue $49.1M (+20%); guides for 20% growth in FY2023
Record annual revenue $49.1M, up 20% YoY; Q4 revenue $12.9M, up 22% from $10.6M.
Champions Oncology Q3 revenue record $13.2M, up 22% YoY; adj. EBITDA $1.5M
Revenue of $13.2M for quarter ended Jan 31, 2022, a 22% increase from $10.8M in prior year.
Champions Oncology reports record Q2 revenue $11.8M, up 17% YoY; operating income $263K
Record quarterly revenue of $11.8M, up 17% from $10.1M year ago.
Champions Oncology annual meeting results: all proposals approved by shareholders
All seven director nominees elected; Scott R. Tobin received highest support (8,518,378 votes).
Champions Oncology Q1 revenue record $11.3M, up 18% YoY; non-GAAP op income $422k
Record quarterly revenue of $11.3M, +17.9% YoY, driven by larger studies and platform expansion.
FY2021 revenue $41.0M, up 28% from $32.1M; Q4 revenue $10.6M, up 21% from $8.8M.
Champions Oncology, Inc. deeply regrets to announce that its President, Mr. Brady Davis, passed away unexpectedly this week.
On October 17, 2023, Champions Oncology, Inc. (the “Company”) announced the hiring and appointment of Brady Davis to serve as the Company’s President, effective as of October 9, 2023.
Max materiality 0.85 · Median 0.65 · Most common event earnings